Alnylam Pharmaceuticals
ALNY
ALNY
197 hedge funds and large institutions have $3.73B invested in Alnylam Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 69 increasing their positions, 65 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
53% less call options, than puts
Call options by funds: $27.9M | Put options by funds: $59.7M
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Holders
197
Holding in Top 10
1
Calls
$27.9M
Puts
$59.7M
Top Buyers
1 | +$30.6M | |
2 | +$28.6M | |
3 | +$23.2M | |
4 |
DM
Deerfield Management
New York
|
+$20.3M |
5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$12.1M |
Top Sellers
1 | -$67.6M | |
2 | -$64.3M | |
3 | -$39.5M | |
4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19.2M |
5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$14.7M |